Asia-Pacific Gene Therapy Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2026 - 2032)

The Asia-Pacific gene therapy market stood at USD 1.8 billion in 2025 and is expected to grow at 32.8% between 2026 and 2032, reaching USD 13.1 billion by 2032. Three forces sit behind that trajectory: clinical trial activity accelerating across China, Japan, India, and South Korea, viral-vector manufacturing capacity expanding within the region, and regulatory frameworks for advanced therapies maturing alongside both.

The depth of the development base is easy to miss from outside. A 2025 peer-reviewed study identified 1,033 investigator-initiated cell and gene therapy trials conducted by institutions in mainland China alone.

Regulation is moving in step. Japan has built a dedicated framework for regenerative medical products that covers gene therapy, including a conditional and time-limited approval pathway that allows earlier patient access while requiring subsequent efficacy evaluation. Taken together, a widening pipeline, growing manufacturing capability, and supportive approval routes are shifting Asia-Pacific from a trial-site region toward one that develops, approves, and commercialises gene therapies of its own.

Key Insights

In vivo holds the larger type share at 75% in 2025, on direct gene delivery through viral vectors, particularly AAV.

Ex vivo grows faster at roughly 33.0% on genetically modified cell therapies and expanding cell-processing capacity. China's FKC876 and India's NexCAR19 show the region can develop and manufacture CAR-T domestically.

Adenovirus is the largest vector type at 60%, backed by established production processes and clinical experience.

Non-viral vectors grow fastest at roughly 33.2%. Lipid nanoparticles and plasmid DNA offer alternatives to viral delivery, with potential for repeat administration.

Carcinoma is the largest application at 40%, reflecting the regional cancer burden and heavy oncology development activity.

Acute lymphoblastic leukemia grows fastest, tracking CAR-T adoption. The U.S. FDA approved obecabtagene autoleucel in November 2024 for adults with relapsed or refractory B-cell precursor ALL.

Pharmaceutical and biotechnology companies hold 80% of end-user share, given the capital and technical demands of vector manufacturing. Academic institutes and research centres grow faster on public funding and translational partnerships.

China holds the largest country share at 40%. Its Center for Drug Evaluation registered 115 cell and gene therapy clinical trials in 2024, a 42% increase on 2023. In April 2025 the National Medical Products Administration approved BBM-H901, or dalnacogene ponparvovec, for adults with moderate-to-severe hemophilia B. Developed by Shanghai-based Belief BioMed with a recombinant adeno-associated virus vector, it is China's first approved gene therapy for that condition.

India grows fastest at roughly 33.7% on government-backed development and domestic manufacturing. The Department of Biotechnology and BIRAC supported NexCAR19, India's first indigenous CAR-T therapy, which received marketing authorisation from the Central Drugs Standard Control Organisation for relapsed and refractory B-cell lymphomas and leukemia.

Vector diversification is the defining shift. A 2024 review counted approximately 3,900 gene therapy clinical trials completed, ongoing, or approved worldwide through 2023, viral vectors still a substantial proportion, while lipid nanoparticle and GalNAc platforms gain ground.

IQVIA estimates 258 million people across Asia-Pacific are affected by rare diseases, a pool growing more visible as diagnosis rates improve.

Reimbursement is the bottleneck. A peer-reviewed analysis in Cytotherapy notes that Japan and South Korea have reimbursement mechanisms for selected cell and gene therapies following health technology assessment, while coverage remains more limited elsewhere. That gap leaves high upfront costs with patients and slows uptake.

Public money is filling part of it. Japan's AMED programmes have allocated approximately JPY 350 billion to the pharmaceutical startup and drug-discovery venture ecosystem, and India's Department of Biotechnology and BIRAC launched a 2025 joint funding programme under the BioE3 Policy for cell and gene therapy and biomanufacturing.

The market is fragmented. Novartis, F. Hoffmann-La Roche, and Sibiono GeneTech operate through different models spanning global commercialisation, regional partnerships, and localised manufacturing, with no dominant player.

AnGes Inc. agreed with Boehringer Ingelheim BioXcellence in August 2025 to manufacture and supply drug substance for its HGF gene therapy Collategene for peripheral arterial disease. REGENXBIO Inc. partnered with Nippon Shinyaku in January 2025 to develop and commercialise RGX-121 for MPS II in the U.S. and Asia.